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MaCardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracy-
clines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more
speciﬁc than conventional therapies, has revolutionized oncology therapy and dramatically changed cancer prog-
nosis. However, some of these therapies have introduced an assortment of cardiovascular (CV) complications.
At times, these devastating outcomes have only become apparent after drug approval and have limited the use of
potent therapies. There is a growing need for better testing platforms, both for CV toxicity screening and for
elucidating mechanisms of cardiotoxicities of approved cancer therapies. This review discusses the utility of available
nonclinical models (in vitro, in vivo, and in silico) and highlights recent advancements in modalities like human stem
cell-derived cardiomyocytes for developing more comprehensive cardiotoxicity testing and new means of cardio-
protection with targeted anticancer therapies. (J Am Coll Cardiol Basic Trans Science 2016;1:386–98) © 2016 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I n the last decade, there has been a paradigm shiftin cancer treatment from the use of nonselectivecytotoxic agents toward targeted therapies
aimed at cellular pathways that have been hijacked
by the cancer (1). Indeed, in 2015, oncology was a nat-
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Precision Medicine Initiative, a $215 million invest-
ment for individualized approach to patient care (2).m the aCardiovascular Division, Vanderbilt University School of Medicin
nderbilt University School of Medicine, Nashville, Tennessee; cVanderbilt-
Drug Evaluation and Research, U.S. Food and Drug Administration, Whi
rs Tennessee Valley Healthcare System, Nashville, Tennessee; fAccelerati
Clinical and Translational Research, Nashville, Tennessee; gCardiovascu
rsity School of Medicine, Stanford, California; hStanford Cardiovascular
nford, California; and the iDivision of Cardiovascular Medicine, Brigham
ston, Massachusetts. The views expressed in this article do not necessarily
ministration. Dr. Wu has received funding from Sanoﬁ; and sits on the sci
rce has consulted for Ariad and Bristol-Myers Squibb. Dr. Moslehi has c
keda, Ariad, Acceleron, Vertex, Incyte, Rgenix, and Verastem. Dr. Croce ha
iad, Bristol-Myers Squibb, The Medicines Company, Abbott Vascular, and S
y have no relationships relevant to the contents of this paper to disclose
nuscript received March 30, 2016; revised manuscript received May 21, 2Conventional cancer therapies like radiation can
lead to cardiovascular (CV) toxicities due to direct,
nonselective myocardial injury (3). Paradoxically,
several of the novel targeted oncology therapies are
associated with a wide spectrum of CV complications
in humans, which were unanticipated based on
nonclinical (also known as “preclinical”) safety
studies (4,5). Such discrepancies highlight thee, Nashville, Tennessee; bCardio-Oncology Program,
Ingram Cancer Center, Nashville, Tennessee; dCenter
te Oak, Maryland; eResearch Medicine, Veterans Af-
ng Drug Repurposing Incubator, Vanderbilt Institute
lar Division, Department of Medicine, Stanford Uni-
Institute, Stanford University School of Medicine,
and Women’s Hospital, Harvard Medical School,
represent an ofﬁcial position of U.S. Food and Drug
entiﬁc advisory board of Stem Cell Theranostics. Dr.
onsulted for Novartis, Pﬁzer, Bristol-Myers Squibb,
s received funding from Ariad; and has consulted for
t. Jude Medical. All other authors have reported that
.
016, accepted May 23, 2016.
AB BR E V I A T I O N S
AND ACRONYM S
CML = chronic myeloid
leukemia
CRISPR = clustered regularly
interspaced short palindromic
repeats
CTCAE = Common
Terminology Criteria for
Adverse Events
CV = cardiovascular
FDA = Food and Drug
Administration
hERG = human ether-à-go-
go-related gene
NRVM = neonatal rat
ventricular myocytes
PSC-CM = pluripotent stem
cell-derived cardiomyocyte
tyrosine kinase inhibitor
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387limitations of current nonclinical strategies in pre-
dicting cardiotoxicities.
Here, we discuss new insights on CV safety in the
development of novel targeted anticancer drugs.
Successful and efﬁcient drug development is predi-
cated on establishing nonclinical models that can be
high-throughput, cost-effective, and comparable to
human physiology for the purposes of clinical efﬁcacy
and safety. In addition, these models must help in
understanding mechanisms of CV toxicities and
strategies for CV toxicity protection. We explore
drug-induced cardiotoxicity testing strategies and
review the existing nonclinical models (in vitro,
in vivo, and in silico), which focus on identifying CV
complications with high mortality risk such as sudden
cardiac death secondary to arrhythmia and heart
failure (Figure 1). In particular, we highlight recent
advances in human pluripotent stem cell-derived
cardiomyocytes (PSC-CMs) as a revolutionary
in vitro model that can improve cardiotoxicity
assessment via personalized medicine and discuss
the merits of in vivo and in silico models. Combining
data from these respective methods will ensure a
better translation to improving patient safety. Last,
we conclude with a discussion of the clinical impli-
cations of monitoring and reducing CV toxicities
gleaned from nonclinical studies.
THE EMERGENCE OF CARDIO-ONCOLOGY
Over the past several decades, improved under-
standing of the cellular and molecular biology un-
derlying various types of cancer has led to rapid
advancements in drug discovery and treatment efﬁ-
cacy. From 1991 to 2012, the overall cancer death rate
declined by 23% (6). In the United States alone, there
were 14.5 million cancer survivors in 2014, with a
projected 19 million survivors by 2024 (7). Cardio-
oncology (CV and cardiometabolic care of cancer pa-
tients), also called oncocardiology, has emerged as a
new medical discipline for several reasons. First,
cancer survivors are at risk of CV disease because CV
disease is prevalent in the general population. Sec-
ond, both conventional and novel cancer therapies
are associated with CV and metabolic toxicities
(Table 1). These adverse sequelae include acute and
chronic CV toxicities and include a variety of com-
plications such as cardiomyopathy, coronary and pe-
ripheral vascular disease, conduction abnormalities,
thrombosis, hypertension, and metabolic disorders
(4,8). However, because novel cancer drugs can
revolutionize treatment and prolong life, cardiotox-
icity risk must be carefully weighed against the
overall beneﬁt of cancer treatment.Within the same class of “targeted” thera-
pies, the CV toxicity can be complex. This is
illustrated in the case of small molecular in-
hibitors targeting tyrosine kinase pathways
(so-called TKIs or tyrosine kinase inhibitors),
used for the treatment of chronic myeloid
leukemia (CML). Imatinib, a ﬁrst-in-class TKI
targeting the ABL1 kinase, which is aberrantly
activated in CML, revolutionized treatment
by roughly doubling the 5-year survival rates
of newly diagnosed CML to 89% (9). Subse-
quently, second- (nilotinib, dasatinib, and
bosutinib) and third- (ponatinib) generation
TKIs were developed for CML treatment.
Initially, these TKIs were developed to over-
come imatinib resistance, but given their
greater potency against ABL1 kinase, they
were positioned for front-line therapy in
CML. However, while imatinib carries mini-
mal CV risk, dasatinib is associated with pulmonary
hypertension, and nilotinib is associated with hy-
perglycemia and vascular events (5). Ponatinib held
great promise as an ideal TKI for CML treatment given
its potent activity in all patients, including those who
had developed resistance to other TKIs. Indeed, in
late 2012, ponatinib achieved approval through the
U.S. Food and Drug Administration (FDA) Accelerated
Approval pathway. However, in the fall of 2013, in a
subsequent phase 2 study, at a median follow-up of
28 months, 19% of patients had serious vascular
events, including cardiovascular (10%), cerebrovas-
cular (7%), and peripheral vascular (7%) events,
leading to transient suspension of ponatinib market-
ing in the United States (10). Nevertheless, given
ponatinib’s efﬁcacy in TKI-resistant patients (and
speciﬁcally, for one “gatekeeper” mutation, BCR-
ABL1T315I), the sale of ponatinib resumed, although
under narrower indications, with a boxed warning
regarding adverse vascular events.
The experience with TKIs in CML generates several
important issues that apply to all new cancer thera-
pies. A TKI with a novel mechanism that demon-
strates unprecedented activity in disease areas of
highly unmet need has a beneﬁt-to-risk acceptability
proﬁle that is different from the second-generation
drug in that same class. As other drugs with similar
mechanisms are developed for the same cancer type,
it is expected that there will be an improvement in
the safety proﬁle. To achieve this goal, a more robust
CV monitoring plan needs to be implemented during
the nonclinical and early clinical trials of newer
compounds of the same class (Table 2). Finally, un-
derstanding the mechanisms of CV toxicities that do
TKI =
FIGURE 1 The Need for More Effective Methods of Nonclinical Screening in Cancer
Treatment-Related Cardiotoxicities
There are numerous in vivo, in vitro, and in silico models that can be used for both
nonclinical testing of CV toxicities and follow-up investigations of underlying mechanisms,
which can be used to develop cardioprotective therapies. IND ¼ investigational new drug;
NDA ¼ new drug application.
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protective strategies during clinical trials and clinical
use. In 2016, better platforms are needed to both
screen for and understand mechanistically CV toxic-
ities associated with novel cancer therapies.
THE CURRENT STANDARD FOR NONCLINICAL
TESTING: A MOVING TARGET IN
ONCOLOGY DRUGS
In an effort to achieve greater harmonization in the
interpretation and application of technical guide-
lines, requirements for pharmaceutical product
development and approval by regulatory authorities,
the International Council for Harmonization (ICH),
with representation from the FDA, developed multi-
ple standardized regulatory guidelines. Two such
guidelines, ICH S7A and S7B, provide recommenda-
tions for nonclinical safety pharmacology studies that
assess adverse drug effects on vital organs (11,12).
With regard to CV toxicities, ICH S7A describes eval-
uations of blood pressure, heart rate, and electrocar-
diograms in animals. If adverse CV effects are
suspected, then follow-up studies may include effects
of the drug on such CV parameters as cardiac output,
ventricular contractility, and vascular resistance
(11). ICH S7B focuses on effects of drugs on the po-
tential for delayed ventricular repolarization via 2components, an in vitro electrophysiology test
measuring drug effects on the human ether-à-go-go-
related gene (hERG) potassium channel, which con-
ducts the rapid delayed rectiﬁer current (IKr), and an
in vivo QT assay in an animal model (12).
Nonclinical safety studies for oncology drugs often
differ from that of drugs for nononcologic indications,
given the associated mortality and morbidity in pa-
tients with advanced cancer, where there may be
limited therapeutic options. The ICH S9 Guidance,
“Nonclinical Evaluation for Anticancer Pharmaceuti-
cals,” provides recommendations on the nonclinical
testing of anticancer drugs to expedite their devel-
opment for patients with advanced disease with
limited therapeutic options (13). Under ICH S9, stand-
alone safety pharmacology studies outlined in ICH
S7A and/or S7B are not required to support a ﬁrst-in-
human clinical trial. Cardiovascular measurements
can be incorporated into general toxicology studies,
with typical durations of 4 weeks to support Phases
1/2 clinical trials and 3 months to support Phase 3
clinical trials and marketing approval. Patients
enrolled in Phase 1 clinical trials for anticancer ther-
apies typically have relapsed or refractory disease
and limited therapeutic options. The level of accept-
able risk of an investigational treatment in this
setting does not generally warrant additional assess-
ments of potential CV toxicity. Nevertheless, ICH S9
states that if there are cardiotoxicity concerns about
a speciﬁc drug, then safety pharmacology studies
described in ICH S7A and/or S7B should be considered
(13). In practice, decision making is considered on an
individual basis for each drug by balancing the po-
tential efﬁcacy in treating a potentially lethal cancer
versus acute and/or chronic cardiovascular toxicity.
In cases where speciﬁc concerns of CV effects are
present and the drug is being investigated in a patient
population for whom clinical management of these
CV toxicities may beneﬁt from further characteriza-
tion in nonclinical studies, a more comprehensive
evaluation of hemodynamics and mechanical and
electrical functions may be warranted.
In the following section, we discuss the estab-
lished and emerging methods to examine potential
cardiotoxic effects of cancer drugs (Table 2). We
admit that each model system described here has
limitations and believe that a combination of the
methodology may be necessary to screen for car-
diotoxic effects of novel compounds as well as to
elucidate mechanisms of cardiotoxicity for existing
ones.
IN VITRO MODELS. Isolated cardiomyocytes, in-
cluding primary cardiomyocytes established from
TABLE 1 Select Classes of Drugs and Their Reported Cardiotoxicities in Drug Labels
Class of
Anticancer Drug Example
Initial FDA
Approval* Boxed Warning* W and P Label*
Alkylating agents Cyclophosphamide 1959 Myocarditis, pericarditis, pericardial effusion, arrhythmias,
and CHF
Antimetabolites 5-ﬂuorouracil (5-FU) 1962 Myocardial ischemia, angina
Anthracyclines Doxorubicin 1974 CHF Arrhythmia
Liposomal doxorubicin 1995 CHF
Epirubicin 1999 CHF Arrhythmia, thrombophlebitis
Taxanes Paclitaxel 1992 Severe conduction abnormalities, hypotension, bradycardia,
and HTN
HER2 inhibitors Trastuzumab 1998 CHF Cardiac dysfunction, arrhythmia, HTN
Pertuzumab 2012 Cardiac dysfunction
Ado-trastuzumab emtansine 2013 LV dysfunction
Tyrosine kinase inhibitors (TKIs) Imatinib 2001 Edema, CHF, hypereosinophilic cardiac toxicity
Dasatinib 2006 Cardiac dysfunction, PAH, QT prolongation, ﬂuid retention
including pleural and pericardial effusion
Nilotinib 2007 QT prolongation, torsades
de pointes, sudden death
Ventricular repolarization abnormalities, cardiac and arterial
vascular occlusive events, ﬂuid retention including pleural
and pericardial effusion
Crizotinib 2011 Bradycardia, QT prolongation
Ponatinib 2012 Arterial thrombosis
(fatal MI, stroke)
CHF, HTN, ﬂuid retention, arrhythmia
Cabozantinib 2012 Severe hemorrhage Arterial thromboembolic events (MI, stroke), HTN
Ibrutinib 2013 Atrial ﬁbrillation
VEGF signaling pathway inhibitors Bevacizumab 2004 Severe hemorrhage MI, stroke, DVT, HTN
Sorafenib 2005 Ischemia, QT prolongation, HTN
Sunitinib 2006 Ischemia, CHF, QT prolongation, torsades de pointes, HTN
Pazopanib 2009 QT prolongation, torsades de pointes, cardiac dysfunction,
HTN, arterial and venous thrombotic events
Vandetanib 2011 QT prolongation, torsades
de pointes, sudden deaths
Ischemic cerebrovascular events, hemorrhage,
heart failure, HTN
Axitinib 2012 HTN, arterial and venous thrombotic events, hemorrhagic
events
Regorafenib 2012 Myocardial ischemia, HTN, hemorrhagic events
mTOR inhibitors Temsirolimus 2007 Hyperglycemia, hyperlipidemia
Everolimus 2009 Hyperglycemia, hyperlipidemia, hypertriglyceridemia
Immunomodulators Thalidomide 1998 DVT, PE MI, stroke, bradycardia
Lenalidomide 2005 DVT, PE
Pomalidomide 2013 DVT, PE
Proteasome inhibitors (PIs) Bortezomib 2003 Hypotension, heart failure, few cases of PAH
Carﬁlzomib 2012 Heart failure, myocardial ischemia, PAH, HTN, venous
thrombotic events
Cancer immunotherapies Ipilimuab 2011 <1% Pericarditis and myocarditis
Nivolumab 2014
Pembrolizumab 2014
*Data from the U.S. FDA (100). Both boxed warnings and W and P sections of labeling for human prescription drugs are recommended by the FDA as industry guidance to categorize reporting of various
adverse reactions. The boxed warnings highlight serious cardiotoxicities (fatal, life-threatening, or permanently disabling), adverse reactions that can be prevented or alleviated, or use with safety re-
strictions. In addition to the boxed warning, the W and P section describes a discrete set of cardiovascular adverse reactions that are serious or are otherwise clinically signiﬁcant because they have im-
plications for prescribing decisions or for patient management.
CHF ¼ congestive heart failure; DVT ¼ deep vein thrombosis; FDA ¼ Food and Drug Administration; HTN ¼ hypertension; MI ¼myocardial infarction; NA ¼ not applicable; PAH ¼ pulmonary hypertension;
PE ¼ pulmonary embolism; W and P ¼ warnings and precautions.
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389tissue explants and human PSC-CMs, represent a
cost-effective and high-throughput means to assess
cardiotoxic effects of novel drugs. These in vitro
methods also offer the opportunity to understand
on-target and off-target molecular mechanisms in a
manner that optimizes the efﬁcacy and safety of new
cancer drugs. However, given the complexinteractions of novel cancer therapies, not only in the
heart but also other systems such as the vasculature,
the use of 2-dimensional cultures may be limited by
the inability to introduce biomechanical stress like
hypoxia and by the absence of intracellular cross talk
between cardiomyocytes and other CV cells (endo-
thelial cells, ﬁbroblasts, leukocytes).
TABLE 2 Summary of Commonly Used Models of Cardiomyocytes
Platform Cell Type (Source) Utility Advantages Disadvantages (Ref. #)
In vitro
H9C2 Embryonic BDIX rat
heart (primary)
Disease modeling Homogenous and replicating in
culture; preserved cardiac
electrophysiology
Morphology similar to immature
embryonic cardiomyocytes;
different differentiation states
(22–26)
Neonatal rat
ventricular
myocytes
(NRVM)
Neonatal rat ventricular
myocyte (primary)
Disease modeling, drug
discovery and
development
Commercially available, robust in
culture; maintain contractility
Sensitivity to experimental
conditions and perturbations
(e.g., media constituents,
duration of drug exposure,
timing of post-isolation
studies)
(18–20)
Human
cardiomyocytes
Human (primary) Drug discovery and
development
Maintain morphologic integrity
and electrophysiological
properties for a short period;
intact mature cardiac ion
channels
Lack of tissue availability; long-
term culture complicated by
dedifferentiation
(14–16)
hERG assay Chinese hamster ovary
and human embryonic
kidney cells (culture)
Drug discovery and
development
Heterologous expression of
single-ion channels; robust
assay used ubiquitously for
hERG block; high-throughput;
cost-effective
Inadequate for multichannel
interactions of functional
cardiomyocytes; risk of false
positives and false negatives
(30–32)
Stem cell-derived
human
cardiomyocytes
Embryonic and induced
pluripotent stem
cell-derived
cardiomyocytes
(culture)
Regenerative medicine,
disease modeling,
drug discovery and
development
Renewable source of cells with
robust differentiation;
expression of human cardiac-
speciﬁc sarcomeric proteins
and ion channels; spontaneous
contractility
Immature cardiomyocytes with
varying degrees of sarcomeric
organization; heterogeneous
mixture of atrial-, ventricular-,
and nodal-like subtypes
(51–56)
In vivo
Mouse NA Disease modeling, drug
discovery and
development
Xenografted cancer models
available; ease of genetic
manipulation; efﬁcient
breeding; ability to monitor
cardiac parameters (e.g., 12-
lead ECG, blood pressure,
heart rate, cardiac function)
and vasculature
Lack of comorbidities (e.g.,
hypertension, hyperlipidemia,
diabetes); multiple
compensatory mechanisms;
physiologic differences (e.g.,
10x faster heart rate); extreme
nonphysiologic stressors (e.g.,
transverse aortic constriction)
(66–69,71)
Zebraﬁsh NA Disease modeling, drug
discovery and
development
Capacity for high-throughput
phenotyping; expression of
crucial ion channels similar to
other vertebrates; structural
transparency; survival for
several days in absence of
cardiac output and/or presence
of major vascular defects
Anatomic differences (2-chamber
heart); ability for cardiac
regeneration throughout
adulthood
(19,76–78)
In silico
O’Hara-Rudy Human ventricular tissue Drug discovery and
development
High-throughput; accounts for
physiologic and genetic
inﬂuences (e.g., age, gender,
ethnicity, drug-drug
interactions); assessment of
multiple ion channels
Limited data on toxicity screening;
lack of established database
and standardized parameters
(e.g., cell type, experimental
conditions)
(80,81)
ECG ¼ electrocardiogram; hERG ¼ human ether-à-go-go-related gene; NA ¼ not applicable.
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390Pr imary card iomyocytes . The use of primary adult
human cardiomyocytes would be most ideal for
in vitro toxicity screening for several reasons. These
cells maintain their morphological integrity,
possess all of the mature cardiac ion channels to
detect any multichannel effects, and function elec-
trophysiologically similar to native environment
(14–16). In practice, their utility in nonclinical drug
testing has been nonexistent due to a combination of
scarcity of human cardiac tissue donors and technical
difﬁculties such as limited number of passages andrapid de-differentiation in culture (17). For this
reason, primary cells from other species at various
stages of development (neonatal, adult) have been
used, such as neonatal rat ventricular myocyte
(NRVM). In one recent study, NRVM was used to show
that doxorubicin caused cardiotoxicity through
mitochondrial iron accumulation, which is reversible
by decreasing iron levels through drugs like dexra-
zoxane (18). NRVMs were also used to show that
sorafenib-induced toxicity is mediated through inhi-
bition of the Raf/MEK/ERK pathways (19). NRVMs can
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391be phenotyped for cardiotoxicity by several means,
including cell death or indirectly, for example, by
measuring cytosolic lactate dehydrogenase release
into the medium (20). While NRVMs are commercially
available and maintain contractility in culture, a ma-
jor caveat is that these cells can be overly sensitive to
perturbations such as medium and experimental
conditions. Also, it is unclear how much these
cells recapitulate human cardiomyocytes. In general,
the preparation and isolation of primary cells are
time-consuming, costly, and technically difﬁcult, as
enzymatic digestion disrupts the cell membrane
permeability for ion exchange (21).
Cel l l ines . There are numerous rodent and human
cell lines that have been established to further char-
acterize cardiac biology, which overcome the limited
proliferative nature of primary cardiomyocytes. One
such model is the H9c2 cell line derived from em-
bryonic BDIX rat heart tissue, which has been used to
study doxorubicin-induced cardiotoxicity (22–24) and
CV toxicity protection through inhibition of endo-
plasmic reticulum stress (25). Studies using H9c2 cells
have also shown that newer TKI-related cardiac
toxicity may be the direct result of functional mito-
chondrial impairment (26). While these cardiomyo-
blasts are a homogenous and replicating culture
population expressing cardiac ion channels, H9c2
cells are less mature and morphologically distinct
from cardiomyocytes (27).
For the purpose of assessing proarrhythmic risk, 2
of the most commonly used cell lines are Chinese
hamster ovary and human embryonic kidney cells,
which can be genetically modiﬁed to overexpress
single-ion channels such as hERG and quantify drug
effects on these channels (28,29). However, this is an
imperfect system because heterologous expression of
single-ion channels cannot adequately recapitulate
the complex nature of multichannel interactions
within functional cardiomyocytes. Consequently,
drugs screening using these hERG-expressing Chi-
nese hamster ovary and human embryonic kidney
cells can lead to false positives (e.g., verapamil),
resulting in high attrition rate in drug development
process and false negatives (e.g., alfuzosin), resulting
in market release of potentially hazardous drugs
(30–33). Furthermore, these immortal cell lines lack
the intrinsic machinery and physiology of functional
cardiomyocytes to detect other cardiac abnormalities.
Promising new platform: human stem cell-derived
cardiomyocytes, advantages and disadvantages. In
recent years, the robust derivations of human car-
diomyocytes from embryonic stem cells and induced
PSC-CMs among other somatic cells have paved the
way for major breakthroughs in drug developmentand toxicity screening (34–38). These cardiomyocytes
hold great promise because they originate from a
renewable source of pluripotent cells, are genetically
speciﬁc to the donor patient, and can be generated in
unlimited quantities. In many ways from structure to
function, they are more similar to adult human car-
diac physiology than that of nonhuman primary
cardiomyocytes. Both types of PSC-CMs express
cardiac-speciﬁc sarcomeric proteins and ion chan-
nels (39,40). Functionally, stem cell-derived CMs
exhibit calcium ﬂux, excitation-contraction coupling,
and action potential parameters that are similar
to those of human ventricular myocytes (41,42).
Human PSC-CMs offer an in vitro platform that is
scalable to meet industrial needs for cardiotoxicity
screening.
Despite their scalability, in 2016, stem cell-derived
cardiomyocytes remain imperfect for a number of
reasons. The cells can be highly variable, and varia-
tions in phenotyping, maturity level, and tissue
source (atrial, ventricular, and nodal) can alter results
and affect reproducibility (41,43). Morphologically,
PSC-CM immaturity is evident by their small cell size
and varying degrees of sarcomeric organization,
which can inﬂuence impulse propagation, action po-
tential depolarization rate, and contractile force (44).
PCS-CM do not express all ion channels in the same
density or ratio as human ventricular myocytes. This
disparity in channel expression may alter PSC-CM
responses to proarrhythmic drugs (45). Long-term
(1-year) culture of cardiomyocytes enhances pheno-
typic maturation, and this or similar techniques may
eventually provide for an optimized PSC-CM cell
substrate that can be used routinely in drug devel-
opment and safety testing (46).
Revolut ion iz ing persona l i zed medic ine . The
ability to generate patient-speciﬁc PSC-CMs creates
the opportunity for a “personalized” approach to
characterizing drug-induced toxicities (Figure 2). This
personalized PSC-CM approach parallels pharmaco-
genomic efforts to understand the role of genetics in
individual patient drug responses. Because patient-
derived PSC-CMs possess the patient-speciﬁc genetic
variations, cardiotoxicity testing in these cells may
allow for in vitro evaluation of drug efﬁcacy or safety
for a particular individual (47). Sex and ethnic dif-
ferences of cancer drug efﬁcacy and safety have been
well documented, and use of patient-derived PSC-
CMs may enable assessment of the genetic and mo-
lecular basis sex- and ethnicity-based variable effects
(48–50).
In proof-of-principle investigations, PSC-CM
studies detected the cardiotoxicity of drugs that are
arrhythmogenic (51–56). One study demonstrated that
FIGURE 2 Promising Personalized iPSC-CM Model for Assessing Cardiotoxicity
Patient-derived somatic cells can be reprogrammed to induced pluripotent stem (iPS) cells by using Yamanaka’s cocktail of transcription factors
and then robustly differentiated into cardiomyocytes (iPSC-CMs) while retaining the individual’s genetic composition. Drug effects on these
cells can be assayed through an expanding repertoire of phenotypic outputs to: 1) address whether there are any CV toxicities; 2) if so, their
underlying mechanism; and 3) evaluate for potential cardioprotective agents. CV ¼ cardiovascular.
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syndrome, hypertrophic cardiomyopathy, or dilated
cardiomyopathy are more susceptible to known car-
diotoxic drugs than those cells of healthy patients
(53). They also suggest that in direct comparison,
disease-speciﬁc PSC-CMs predicted adverse drug re-
sponses more accurately than the conventional hERG
testing and are able to correctly discriminate drugs
like verapamil and alfuzosin as safe and QT prolong-
ing, respectively. Similarly, another study using PSC-
CMs to assess cardiotoxicity of 4 TKIs showed that
each drug has its own unique toxicity proﬁles with
distinct mechanisms including formation of reactive
oxygen species, apoptosis, lipid accumulation,
proarrhythmia, and altered contractility (54). The
severity of cellular PSC-CM cardiotoxicity seems to
correlate with clinical reports of cardiac adverse
events. Several PSC-CM safety/screening studies have
also used 96-well plates capable of measuring real-
time impedance as a primary screen for contractilityand arrhythmia (55,56). This impedance assay, which
has higher throughput than conventional patch clamp
techniques, showed superior prediction of drug
proarrhythmic potential versus standard hERG
testing. A recent study of breast cancer patients
showed that patient-speciﬁc PSC-CMs display a pre-
dilection for cardiotoxicity that correlates with the
presence of cardiotoxic effects in individual patients.
PSC-CMs derived from individuals with breast cancer
suffered more doxorubicin-induced toxicity than
PSC-CMs derived from patients who did not experi-
ence toxicity. The cells from patients who experi-
enced cardiotoxicity had decreased cell viability,
impaired mitochondrial function, altered metabolic
activity, impaired calcium handling, and increased
reactive oxygen species production (57).
There are currently several initiatives focused on
establishing banks of induced pluripotent stem cell
(iPSC) lines from healthy individuals and from pa-
tients with cancer diagnoses (58). The Stanford
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393Cardiovascular Institute, for example, is creating a
biobank of 1,000 patients with various types of car-
diovascular diseases (Stanford Cardiovascular Insti-
tute Biobank, Stanford School of Medicine, Stanford,
California). Inevitably, there will be substantial het-
erogeneity in the cells produced due to differences in
factors like tissue source and methods of reprogram-
ming and differentiation. While the disease state may
contribute to the observed phenotype during drug
testing, there needs to be a standardized guideline for
characterizing PSC-CMs to differentiate drug-
dependent versus drug-independent effects. A so-
phisticated approach using new genome editing
technology, clustered regularly-interspaced short
palindromic repeats (CRISPR-Cas9), enables the cre-
ation of isogenic iPSCs with any desired mutation in
otherwise genetically identical lines (59). Despite
their potential as a drug development tool, PSC-CM
technology has not matured to the point where it
can be routinely incorporated into preclinical drug
efﬁcacy or cardiotoxicity testing.
IN VIVO MODELS. Similar to in vitro assays, animal
models, both rodent and nonrodent, are widely used
to detect cardiotoxicities, although more highly pre-
dictive models are needed because cancer patients
often have comorbidities, which cannot be assessed
in healthy animals. Animal studies enable examina-
tion of complex biological systems such as tumor
growth, metastasis, inﬂammation, and thrombosis
(11–13). By far the most valuable insight an animal
model offers over cells in a dish is the full comple-
ment of molecular, biochemical, and physiological
systems. In addition to monitoring hemodynamics
and continuous electrocardiography using jacketed
external telemetry, in vivo models can also evaluate
many other crucial parameters such as vascular tox-
icities including hypertension and atherosclerosis.
This is particularly relevant in the screening of novel
kinase inhibitors, many of which have on- or
off-target effects on the CV system. While many of the
animal models in cardio-oncology have focused on
“myocardial” and “arrhythmogenic” toxicity, better
animal models are needed to elucidate vascular and
metabolic toxicities with newer agents (such as
second-generation TKIs used in CML).
Rodent models . Laboratory studies in rats and mice
have been one of the quintessential cornerstones of
biology. Rodent models have been widely used due to
their relative physiologic similarities to humans, ease
for genetic manipulations, and relative efﬁciency
of breeding and maintenance compared with larger
mammals like primates. Studies in rats have been
used extensively to explore various aspects of
anthracycline-induced cardiotoxicity (60), includingstudies showing that hypertensive rats are more
sensitive than normotensive rats to the chronic car-
diotoxic effects of doxorubicin (61). Additionally,
sexual dimorphism has been reported, with males
developing much more signiﬁcant cardiomyopathy
and experiencing higher mortality (62). Small ana-
lyses with 39 total anticancer agents suggest that ro-
dents alone can predict a safe Phase I trial starting
dose and the majority of toxicities that become dose
limiting with treatment (63,64). In general, rat toxi-
cology studies in conjunction with dog studies have
been adequate in deﬁning safety/dosing parameters
for clinical trials (65).
Similarly, mice have been used for decades to
examine the mechanism of cardiotoxicities of con-
ventional therapies such as anthracyclines and ra-
diation. For example, the use of mice has allowed
mechanistic understanding of doxorubicin-induced
cardiac injury, implicating the role of free radicals
(66), topoisomerase-IIb (67), and radiation-induced
CV injury (68). Crone et al. (69) created a mouse
model with ventricular-restricted deletion of HER2
(also called ErbB2) receptor tyrosine kinase, over-
expression of which plays an important role in the
development and progression of certain aggressive
types of breast cancer. This mouse model allowed
for better understanding of the cardiomyopathy
associated with the breast cancer therapy trastuzu-
mab, a humanized monoclonal antibody speciﬁc for
the extracellular domain of HER2, implicating HER2
as a previously unappreciated signaling pathway in
cardiac biology. Ideally, transgenic mouse strains
can provide valuable insights into the speciﬁc path-
ways that lead to CV toxicities. In addition, physio-
logical parameters such as blood pressure, heart
rate, and cardiac function can be measured, and
biomarker serologic testing may predict risk of risk
of actual events.
Despite the utility of preclinical rodent studies, data
must be interpreted with caution, because intrastrain
mouse genetic differences (or genetic differences from
humans) can mask potential side effects or suggest
toxicities that may or may not be seen in humans. This
pitfall of rodent research may be more accentuated in
newer targeted therapies, which act on speciﬁc
signaling pathways that may vary widely between
species. For example, the breast cancer therapy tras-
tuzumab only recognizes human HER2, which negates
the ability to study cardiotoxic mechanisms in mice
(J. Moslehi, unpublished data, May 2016). A meta-
analysis of 16 clinical trials using the breast cancer
therapy sunitinib demonstrated increased risk of
congestive heart failure (70); however, mouse studies
showed minimal changes in left ventricle ejection
Sheng et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 5 , 2 0 1 6
Cardiovascular Toxicity of Anticancer Drugs A U G U S T 2 0 1 6 : 3 8 6 – 9 8
394fraction (71). Several confounders may account for
these differences between the preclinical studies and
clinical trials. Patients receiving targeted therapies
like sunitinib are older with multiple comorbidities
such as hypertension, hyperlipidemia, and diabetes.
Mouse models to simulate those conditions are often
the extremes, including genetic deletion of kinases (as
opposed to pharmacological inhibition). Future
studies are needed to address the translatability of
cardiotoxicity ﬁndings in rodents to humans.
Zebraﬁsh . Zebraﬁsh (Danio rerio) is a useful animal
model system for studying CV development, genetics,
and cardiotoxicity. It was initially popularized for its
utility in large-scale forward genetic screens (72,73).
One of its major advantages over existing animal
models in cardiotoxicity screening is the capacity for
high-throughput phenotyping. Zebraﬁsh are small
enough for 384-well plates, and some strains remain
transparent throughout adulthood, which enables
visualization of cardiovascular phenotypic traits (74).
In addition, zebraﬁsh are able to survive in the
absence of cardiac output and in the presence of
major vascular defects for several days, allowing for
enhanced characterization of abnormalities otherwise
fatal in mammals. Despite anatomic and physiological
differences (zebraﬁsh heart only has 2 chambers and
maintains ability to regenerate throughout adult-
hood), the cardiomyocytes still express crucial ion
channels similar to that of other vertebrates including
voltage-gated sodium, L-type and T-type calcium,
and potassium channels (75). In contrast to other
vertebrate models, zebraﬁsh develop rapidly, forming
a fully functioning heart within 26 h of fertilization,
and can be maintained cost-effectively.
There are several studies that suggest zebraﬁsh can
be used to evaluate drug cardiotoxicity. For example,
zebraﬁsh can develop signs of cardiomyopathy and
electrophysiological abnormalities following treat-
ment with of TKIs. In one study of 100 small mole-
cules, 22 of 23 drugs that caused clinical QT
prolongation caused bradycardia in zebraﬁsh by
altering the repolarizing potassium current (76).
Zebraﬁsh studies also detected drug-drug in-
teractions leading to QT prolongation such as those
between erythromycin and cisapride and between
cimetidine and terfenadine. A more recent study in
zebraﬁsh discriminated between TKIs that caused
cardiomyopathy (sunitinib and sorafenib) versus
those that do not (geﬁtinib) (19). The one caveat is
that while the zebraﬁsh kinome is very similar to that
of human, subtle species differences in amino acid
sequence could affect the binding interaction, thus
leading to under- or over-estimation of toxicity (77).As shown by the studies cited earlier, quantitative
phenotyping of zebraﬁsh illustrates the potential to
assess cardiotoxic effects of new classes of targeted
therapies.
In addition to screening for toxicity, the high-
throughput nature of zebraﬁsh enables chemical
screening of large numbers of compounds for efﬁcacy
or cardiotoxicity research to explore novel means of
cardioprotection and to better elucidate mechanisms
of cardiotoxicity. In this regard, zebraﬁsh high-
throughput chemical screening in a doxorubicin-
induced cardiomyopathy model identiﬁed visnagin
as a new cardioprotective compound. Visnagin mod-
ulates mitochondrial malate dehydrogenase, a key
metabolic enzyme during injury responses (78).
Despite promising early studies, more research is
necessary to correlate establish and validate the
translational utility of the zebraﬁsh cardiotoxicity
screening.
IN SILICO MODELS. With the increasing availability of
large datasets, in silico models, a term for modeling
via computer simulations, have garnered more atten-
tion and interest from researchers and pharmaceutical
industry alike within the past decade as a method of
evaluating CV safety (79). In silico models offer the
distinct advantages of being high-throughput and
testing a wide range of potentially relevant scenarios.
Computer simulations could factor in physiologic and
genetic inﬂuences such as age, gender, and ethnicity,
as well as provide an opportunity to explore drug-drug
interactions. One established mathematical model,
the O’Hara-Rudy model, uses experimental data
collected from 140 human hearts to recapitulate a
range of physiologic responses to changes in pacing
rate and predict arrhythmic behavior with drug
blockage on 14 types of outer membrane currents (80).
With respect to the risk of torsades, several studies
have suggested that voltage clamp data measured
from a drug’s effect on multiple ion channels would
provide a more accurate assessment of the overall ef-
fects on ventricular repolarization that otherwise may
not be apparent from analyzing any individual current
(i.e., Ikr) (81,82). One in silico study used a logistic
regression approach to examine the cardiotoxicity of
55 drugs (32 torsadogenic and 23 nontorsadogenic)
through 3 cardiac channels (IKr, fast sodium, and
L-type calcium). That in silico study showed beneﬁt of
simulating multiple ion channels and improved the
false positives and false rate compared with in silico
testing of a single-ion channel (81). However, in silico
analyses are only as valid as the dataset used to
construct the simulation, and a regulated, open source
database with standard testing protocols will need to
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395be developed before in silico testing can be relied on
for drug development and safety purposes.
FUTURE DIRECTION OF
NONCLINICAL TESTING: EMPHASIS ON
MECHANISTIC UNDERSTANDING
With a mixture of established and emerging models,
advancements in nonclinical testing should focus on
2 aspects. The ﬁrst is establishing better models that
allow for more accurate prediction of cardiotoxicities
during research and development. For QT prolonga-
tion testing, for example, one promising approach
under development is the “Comprehensive in vitro
Proarrhythmia Assay” (CiPA), which suggests the
following: 1) expanding in vitro testing to multi-
channel assays; 2) adding in silico simulations to
assess proarrhythmic liability; and 3) incorporating
human PSC-CM conﬁrmatory studies (83). It remains
to be seen whether some of the newer models like
PSC-CMs and in silico assays will lead to revisions in
cardiotoxicity testing guidelines.
The second component should be focused on better
mechanistic characterization of the toxicities using
some of the promising new models like PSC-CMs and
zebraﬁsh. As new toxicities emerge with the use of
TKIs, even during clinical trials, investigators can
then conduct focused nonclinical studies to elucidate
their underlying mechanisms of action. In the pro-
cess, zebraﬁsh screening may also provide opportu-
nities for identifying new agents like visnagin that
prevents or mitigates CV side effects (78). This will be
crucial to pave the path for more detailed clinical
studies and to develop best practices of managing
these toxicities.
CLINICAL MONITORING AND
PREVENTION OF CARDIOTOXICITIES
Novel targeted therapies have revolutionized treat-
ment for various cancers, leading to increased survival
in many cancer subtypes, to the point where comorbid
CV diseases compete with the cancer as a leading
cause of morbidity and mortality (84). As a result,
cardio-oncology clinical programs are emerging across
the country that serve as an interdisciplinary approach
for managing CV comorbidities while treating with
necessary life-saving therapies (85). Because CV dis-
eases are common in the general population, it can be
hard to dissect treatment-associated cardiotoxicities
from treatment-independent CV events. Therefore, a
major aim of cancer clinical trials is to identify po-
tential treatment-associated CV toxicities. In this re-
gard, clinical and population cardiotoxicity studiesshould often accompany and feed nonclinical model
systems.
The ﬁrst and foremost priority to achieving this
goal is developing comprehensive standards for
assessment of cancer treatment-related CV toxicities.
Oncology trials typically use a guideline called the
Common Terminology Criteria for Adverse Events
(CTCAE), which was developed by the National Cancer
Institute to classify undesired effects with criteria for
qualitative grading the severity of each event; how-
ever, CTCAE often lack standardized quantitative
assessment of the event severity. This concept is
especially an issue with CV toxicities. Previous studies
have varied widely in reported incidence rate of can-
cer therapy-induced cardiotoxicities between 0% and
57%, depending on the study design and factors such
as different classiﬁcations, comorbidities, and follow-
up length (86–90). Furthermore, cardiac studies often
include independent adjudication committees that
help correctly grade a particular CV toxicity, which is
not routinely done in oncology trials (4).
The discrepancies in the CV toxicity assessment of
clinical trials not only obfuscate clinicians’ ability to
identify treatment-associated cardiotoxicities, but
they also compromise any effective assessment of
cardioprotective interventions. In retrospective ana-
lyses with potential for misclassiﬁcation bias, TKIs
like sunitinib are associated with increased risk of
congestive heart failure (RR: 1.81) (70). Such unex-
pected CV side effects need to be validated in
well-designed clinical trials that prospectively follow
patients for adverse CV outcomes. As investigators
work to develop improved preclinical cardiotoxicity
screening strategies, we will need to rely on more
rigorous assessment of CV events clinical trial evalu-
ation of novel cancer drugs.
Better strategies should be implemented for post-
marketing surveillance and vigilance, especially due
to the novelty and chronic administration of many
therapies. For instance, emerging evidence from
long-term studies like the Childhood Cancer Survi-
vors Study suggest that the risk of morbidity and
mortality among survivors continues to increase de-
cades later (91). Due to the lack of an established
protocol for surveillance, many patients may be lost
to follow-up, and true incidence of cardiotoxicities is
probably underestimated. Many approaches are un-
der investigation for utility in clinical monitoring
such as cardiac imaging and biomarker studies,
including measurements of left ventricle ejection
fraction and natriuretic peptides, respectively. Strain
measurements on echocardiography appear to be
promising for early detection of myocardial changes
and prediction of cardiotoxicity in patients receiving
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396cancer treatment (92). In the future, genetic screening
may help to identify at-risk cardiotoxicity patients,
as evidence by the fact that single nucleotide poly-
morphisms associated with protection from or sus-
ceptibility to anthracycline CV toxicity (93–95).
Ultimately, well-designed epidemiologic studies from
prospective trials will be essential to determine the
true incidence, severity, and natural history of
various CV toxicities.
Another emerging model to predict potential car-
diotoxicity of the ever-expanding pipeline of targeted
cancer therapeutics, especially TKIs, is the use of
human genetic information coupled to electronic
health records. For instance, Vanderbilt University
Medical Center’s BioVU, a large, human DNA re-
pository linked to de-identiﬁed electronic health re-
cords within the Synthetic Derivative database can be
used to predict both on-target therapeutic effects as
well as adverse outcomes in man (96–98). Using Bio-
VU as a human genome-phenome analysis platform,
one can carry out a phenome-wide association study
(PheWAS) to determine what clinical phenotypes
were associated with genetic variations in the genes
targeted by drugs. As an example, such analysis
identiﬁed a rare nonsynonymous variant in a kinase
gene that is strongly associated with osteoporosis in
patients, suggesting that pharmacological inhibition
of this kinase could lead to osteoporosis in patients
(C. C. Hong, personal communication, April 2016).
One can easily envision search for potential associa-
tions of drug target genes with cardiovascular out-
comes such as myocardial infarction, sudden cardiac
death, and heart failure. In summary, the emerging
marriage of human genetic data and electronic med-
ical records can be leveraged to gain early humanbiological insights to potential adverse cardiovascular
effects of new therapeutics.
CONCLUSIONS
Moving forward, there is no doubt that both preclinical
testing and clinical detection of cardiotoxicity will
continue to improve. As the focus of anticancer ther-
apies shifts from a broadly cytotoxic approach to more
targeted molecular treatments, there is increasing
concern for unexpected CV toxicities that have been
reported through case reports and retrospective
studies (9,70,91,99). Historically, preclinical safety
testing has focused on in vitro hERG-centric assays and
QT monitoring, and this has resulted in unexpected
cardiotoxicity during clinical trials or in post-market
drug surveillance. In time, new drugs may be able to
harness emerging methods such as in silico, PSC-CMs,
and zebraﬁsh testing to identify potent candidate
agents that have good safety proﬁles. Developingmore
accurate and comprehensive assessment of car-
diotoxicity in nonclinical models may ultimately
reduce costs through early target optimization. In the
future, advances in preclinical testing methods should
be combinedwith heightened assessment of CV events
in oncology trials; these synergistic initiatives will
help to maximize therapeutic impact while also help-
ing to quantify and minimize CV risk for burgeoning
classes of life-saving cancer therapies.
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